截至7月7日收盘，减肥药概念下跌1.10%，位居概念板块跌幅榜前列，板块内，科兴制药、一品红、甘 李药业等跌幅居前，股价上涨的有17只，涨幅居前的有泰恩康、*ST三圣、蓝晓科技等，分别上涨 4.12%、3.21%、2.31%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 中船系 | 5.23 | 同花顺果指数 | -1.53 | | 生物质能发电 | 2.83 | 重组蛋白 | -1.42 | | 2025中报预增 | 2.77 | 减肥药 | -1.10 | | 虚拟电厂 | 2.62 | CRO概念 | -1.07 | | 跨境支付(CIPS) | 2.36 | AI PC | -1.02 | | 抽水蓄能 | 2.26 | AI手机 | -0.99 | | 超超临界发电 | 2.20 | 中国AI 50 | -0.98 | | 租售同权 | 2.20 | 芬太尼 | -0.85 | | 柔性直流输电 | 2.00 | 共封装光学(CPO) | -0.82 | | 特高压 | 1.98 | 创新药 | ...

减肥药概念资金流入榜 | 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 300723 | 一品红 | 14.72 | 5.65 | 16839.73 | 13.25 | | 301263 | 泰恩康 | 3.53 | 5.77 | 13097.62 | 20.64 | | 688136 | 科兴制 | 15.62 | 8.32 | 9780.36 | 14.10 | | | 药 | | | | | | 300765 | 新诺威 | 6.60 | 1.08 | 9256.95 | 12.74 | | 002294 | 信立泰 | 6.19 | 1.26 | 7948.95 | 11.50 | | 002317 | 众生药 | 4.06 | 12.39 | 7284.63 | 5.01 | | | 业 | | | | | | 603087 | 甘李药 | 3.29 | 2.65 | 5907.38 | 7.18 | | | 业 ...

Company Highlights - Hanyu Pharmaceutical expects a net profit of 142 million to 162 million yuan for the first half of 2025, benefiting from increased global market demand and successful product approvals [1] - Taotao Automotive anticipates a net profit growth of 70% to 98% year-on-year for the first half of 2025, driven by enhanced brand influence and improved operational efficiency [2] - Xiaogoods City projects a net profit increase of 13% to 17% for the first half of 2025, attributed to growth in main business revenue and trade fulfillment services [2] - Hongxin Electronics signed contracts totaling 373 million yuan for computing power services through its subsidiaries [3] - Alloy Investment's controlling shareholder will change to Jiuzhou Hengchang, leading to the resumption of trading [3] - Hangzhou High-tech is planning a change in control, with a suspension of trading expected for no more than two trading days [4] - Junpu Intelligent signed a sales framework contract for humanoid robots worth 28.25 million yuan [7] - Lens Technology plans to issue 262 million H-shares globally, with an initial price range set between 17.38 and 18.18 HKD [8] - Saintno Biopharmaceuticals received a drug registration certificate for its product, further enhancing its market competitiveness [12] Investment & Contracts - Shenzhen Energy plans to invest 6.332 billion yuan in upgrading the Mawan Power Plant, aligning with national energy policies [17] - China Railway Construction won a contract worth 3.781 billion yuan for the China-Kyrgyzstan-Uzbekistan railway project [27] - China Railway secured contracts totaling approximately 5.343 billion yuan for the same railway project [28] - Zhongtian Technology's subsidiary won multiple marine energy project contracts totaling about 1.722 billion yuan [29] - Lande Group intends to acquire a 20.1667% stake in Jujia Technology for up to 121 million yuan, enhancing its capabilities in high-performance materials [21][22] Financing & Capital Increase - Yiwei Lithium Energy submitted an application for H-share issuance and listing in Hong Kong [30] - Jiadou Technology plans to issue H-shares and list on the Hong Kong Stock Exchange [30] - Helin Micro-Nano is preparing to issue H-shares for listing in Hong Kong [30] Other Developments - Renfu Pharmaceutical received approval for its midazolam injection in France, with expected annual sales of approximately 33 million USD [31] - Kanghong Pharmaceutical obtained a drug registration certificate for its eye drop product, enhancing its product pipeline in the ophthalmology sector [32]

中国基金报记者 晨曦 大家好！来一起关注上午的市场和最新资讯。 6月20日上午，A股市场窄幅震荡。截至午间收盘，上证指数涨0.08%，深证成指跌0.19%，创业板指跌0.56%。 | A股 港股 美股 全球 | 具合 | 商品三 | | --- | --- | --- | | 内地股票 △ | | | | 行情 资金净流入 | 涨跌分布 | | | 上证指数 深证成指 | 北证50 | | | 3364.83 10032.64 | 1363.90 | | | +2.73 +0.08% -19.32 -0.19% -1.88 -0.14% | | | | 科创50 创业板指 | 万得全A | | | 960.62 2015.47 | 5100.81 | | | -2.32 -0.24% -11.35 -0.56% -2.32 -0.05% | | | | 沪深300 中证500 | 中证A500 | | | 3852.39 5661.02 | 4501.14 | | | +9.30 +0.24% -15.81 -0.28% +1.32 +0.03% | | | | 中证1000 深证100 | 中证红利 | | ...

A股三大指数早盘集体下跌，截至午盘，沪指跌0.86%，深成指跌1.01%，创业板指跌1.10%，北证50指 数跌0.99%。全市场半日成交额8058亿元，较上日放量432亿元。全市场超4600只个股飘绿。 板块题材上，固态电池、PCB概念、石油板块涨幅居前；核聚变、军工、减肥药板块跌幅居前。 NO.1 【比亚迪（002594）概念】 板块内8家涨停，2只连板股，最高连板数为3天3板，涨停股代表：诺 德股份、中京电子。 NO.2 【华为概念】 板块内8家涨停，1只连板股，最高连板数为9天6板，涨停股代表：东信和平、电科 网安（002268）。 盘面上，固态电池板块领涨，诺德股份（600110）、湘潭电化（002125）、丰元股份（002805）涨停。 稳定币概念局部活跃，东信和平（002017）涨停，楚天龙（003040）、安妮股份（002235）涨超5%。 AI硬件端涨幅靠前，逸豪新材（301176）、中京电子（002579）、凯旺科技（301182）涨停，核电板块 跌幅居前，合锻智能（603011）、中核科技（000777）跌停，哈焊华通（301137）跌近15%。减肥药概 念股集体调整，常山药业（3002 ...

截至6月10日收盘，中韩自贸区概念上涨2.30%，位居概念板块涨幅第2，板块内，8股上涨，连云港涨 停，华光源海、青岛金王、日照港等涨幅居前，分别上涨26.88%、3.41%、1.87%。跌幅居前的有新华 锦、海程邦达、好当家等，分别下跌9.34%、3.27%、0.85%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 转基因 | 3.15 | EDR概念 | -2.63 | | 中韩自贸区 | 2.30 | MLOps概念 | -2.56 | | 毛发医疗 | 2.25 | 兵装重组概念 | -2.43 | | 玉米 | 2.18 | 华为盘古 | -2.40 | | 航运概念 | 2.00 | 华为昇腾 | -2.34 | | 高压氧舱 | 1.54 | 国家大基金持股 | -2.28 | | 减肥药 | 1.46 | 星闪概念 | -2.25 | | 重组蛋白 | 1.42 | 汽车芯片 | -2.14 | | 粮食概念 | 1.30 | 华为欧拉 | -2.07 | | 动物疫苗 | 1.29 | ...

| 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 转基因 | 3.15 | EDR概念 | -2.63 | | 中韩自贸区 | 2.30 | MLOps概念 | -2.56 | | 毛发医疗 | 2.25 | 兵装重组概念 | -2.43 | | 玉米 | 2.18 | 华为盘古 | -2.40 | | 航运概念 | 2.00 | 华为昇腾 | -2.34 | | 高压氧舱 | 1.54 | 国家大基金持股 | -2.28 | | 减肥药 | 1.46 | 星闪概念 | -2.25 | | 重组蛋白 | 1.42 | 汽车芯片 | -2.14 | | 粮食概念 | 1.30 | 华为欧拉 | -2.07 | | 动物疫苗 | 1.29 | 成飞概念 | -2.05 | 资金面上看，今日减肥药概念板块获主力资金净流出6.01亿元，其中，23股获主力资金净流入，6股主 力资金净流入超3000万元，净流入资金居首的是乐普医疗，今日主力资金净流入1.76亿元，净流入资金 居前的还有恒瑞医药、甘李药业、泰恩康等，主力资金分别净流入1.64亿元、1 ...

Group 1: Market Performance - The stock of Changshan Pharmaceutical (300255) surged by 20% on June 9, closing at 52.09 yuan per share, with a total market capitalization of 47.874 billion yuan, marking a historical high [1] - The overall index for the weight-loss drug concept rose by 4.66% on the same day, closing at 1263.62 points, indicating strong market interest [1] - Other stocks in the weight-loss drug sector, such as Shengnuo Bio and Tainkang, also saw significant gains, with daily increases of 17.58% and 13.80% respectively [1] Group 2: Industry Trends - The GLP-1 drug market is projected to reach a global scale of over $60 billion by 2025, with China's market expected to hit $4.5 billion, growing at an annual rate exceeding 28% [3] - The Chinese government has initiated a "Weight Management Year" campaign, highlighting the increasing prevalence of obesity and its health implications [3] - The market for weight-loss drugs is becoming increasingly competitive, with over twenty companies developing biosimilars for semaglutide, indicating a shift from a blue ocean to a red ocean market [4][5] Group 3: Company Developments - Changshan Pharmaceutical's stock price increase is attributed to the potential of its GLP-1 drug, Aibennate, in the billion-dollar weight-loss drug market, despite facing fundamental pressures such as debt and cash flow issues [2] - Innovative companies like Heng Rui Pharmaceutical are advancing in the GLP-1/GIP dual-target drug space, with promising clinical trial results showing significant weight loss compared to existing treatments [5][6] - The dual receptor agonist, Masitide, developed by Innovent Biologics, is set to be the first of its kind to enter the market, targeting both GLP-1 and GCG receptors for enhanced weight loss and liver fat metabolism [7]

Core Viewpoint - The weight loss drug concept sector has seen a significant increase, with a rise of 4.66% as of June 9, positioning it as the second-highest gaining sector in the market [1]. Group 1: Market Performance - Within the weight loss drug sector, 48 stocks experienced gains, with Changshan Pharmaceutical reaching a 20% limit up [1]. - Notable gainers include Zhongsheng Pharmaceutical, Meinuo Pharmaceutical, and Shuanglu Pharmaceutical, all hitting the limit up, while Xinnoway and *ST Sansheng were among the few decliners [1]. - The sector's performance is reflected in the daily gainers and losers table, highlighting the overall positive trend in the weight loss drug concept [1]. Group 2: Capital Flow - The weight loss drug sector attracted a net inflow of 237 million yuan from major funds, with 27 stocks receiving net inflows [1]. - Zhongsheng Pharmaceutical led the net inflow with 247 million yuan, followed by Zhifei Biological, Shuanglu Pharmaceutical, and Ganli Pharmaceutical, which also saw significant inflows [1][2]. - The net inflow ratios for leading stocks in the sector were notably high, with Zhongsheng Pharmaceutical at 55.08%, indicating strong investor interest [2][3]. Group 3: Stock Performance Metrics - Key stocks in the weight loss drug sector showed impressive daily performance metrics, with Zhongsheng Pharmaceutical and Shuanglu Pharmaceutical both achieving nearly 10% gains [2][3]. - The turnover rates for these stocks also reflect active trading, with Zhongsheng Pharmaceutical at 3.84% and Shuanglu Pharmaceutical at 7.00% [2][3]. - The data indicates a robust interest in the weight loss drug sector, as evidenced by the high net inflow ratios and significant daily price movements [2][3].

| 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | CRO概念 | 4.73 | 金属铅 | -0.30 | | 减肥药 | 4.66 | 供销社 | -0.05 | | 足球概念 | 4.44 | 金属铜 | 0.07 | | 创新药 | 3.91 | 金属锌 | 0.10 | | 毛发医疗 | 3.82 | 小米汽车 | 0.15 | | 阿尔茨海默概念 | 3.80 | 黄金概念 | 0.21 | | 染料 | 3.71 | 同花顺中特估100 | 0.23 | | 稀土永磁 | 3.45 | 海南自贸区 | 0.25 | | 仿制药一致性评价 | 3.37 | 低辐射玻璃(Low-E) | 0.30 | | 辅助生殖 | 3.33 | 国家大基金持股 | 0.32 | 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 资金面上看，今日供销社概念板块获主力资金净流出1.86亿元，其中，11股获主力资金净流出，净流出 资金居首的是湖南发展，今日主力资金净流出1.45亿元，净流出资金居前的还有亚钾国际、中农立华、 供销大集等 ...